Skip to main content
UCB logo

UCB — Investor Relations & Filings

Ticker · UCB ISIN · BE0003739530 LEI · 2138008J191VLSGY5A09 BR Manufacturing
Open in API
Filings indexed 2,018 across all filing types
Latest filing 2018-02-22 Annual Report
Country BE Belgium
Listing BR UCB

About UCB

https://www.ucb.com/

UCB is a global biopharmaceutical company that focuses on creating solutions for people living with severe diseases, primarily in the fields of neurology and immunology. The company's core activities include the research, development, and commercialization of pharmaceutical and biotechnology products. Guided by a patient-centric and science-driven approach, UCB is committed to innovation and sustainability. Through its UCB Ventures arm, it invests in pioneering technologies and companies with the potential to transform patient care. The company also offers personalized support services to patients and healthcare professionals during their treatment journey with a UCB medicine.

Recent filings

Filing Released Lang Actions
2017 annual report - FR.pdf
Annual Report Classification · 100% confidence The document is titled 'Rapport annuel 2017' (Annual Report 2017) for UCB. It contains a comprehensive overview of the company's performance, including a letter to stakeholders, strategic outlook, financial highlights, and a detailed table of contents referencing consolidated financial statements, management reports, and auditor reports. Given its length, structure, and content, it is clearly the company's official annual report. FY 2017
2018-02-22 French
2017 annual report - NL.pdf
Annual Report Classification · 100% confidence The document is titled 'Jaarverslag 2017' (Annual Report 2017) for UCB. It contains a comprehensive overview of the company's performance, including a letter to stakeholders, strategy, personnel, R&D, financial highlights, and a detailed table of contents referencing consolidated financial statements and auditor reports. It is clearly the full annual report, not an announcement or summary. FY 2017
2018-02-22 Dutch
UCB Transparency Notification Jan 29 2018 ENG.pdf
Major Shareholding Notification Classification · 99% confidence The document is explicitly titled 'Transparency notification' and references 'Article 14 of the law of 2 May 2007 on the disclosure of large shareholdings'. It details changes in the ownership stake of Financière de Tubize SA in UCB, specifically noting the termination of an agreement to act in concert and providing the resulting share count and percentage (35.00%). This content directly corresponds to the definition of a Major Shareholding Notification (MRQ), which covers changes in significant share ownership levels crossing thresholds or related events like the termination of concert agreements affecting those thresholds.
2018-01-29 English
UCB Transparency Notification Jan 29 2018 FR.pdf
Major Shareholding Notification Classification · 98% confidence The document is titled "Déclaration de transparence" (Transparency Declaration) and explicitly references compliance with Article 14 of the Belgian law regarding the disclosure of significant shareholdings ("loi du 2 mai 2007 relative à la publicité des participations importantes"). It details a change in a concert party agreement and the resulting shareholding percentage (35.00%) held by Financière de Tubize SA in UCB SA. This type of filing, which reports changes in significant ownership thresholds by shareholders, directly corresponds to the definition of Major Shareholding Notification (MRQ). Although it is a regulatory disclosure, MRQ is more specific than the general RNS category.
2018-01-29 French
UCB Transparency Notification Jan 29 2018 NL.pdf
Declaration of Voting Results & Voting Rights Announcements Classification · 99% confidence The document is titled "Transparantieverklaring" (Transparency Declaration) and explicitly mentions being based on Article 14 of the law regarding the disclosure of major shareholdings ("openbaarmaking van belangrijke deelnemingen"). It details a change in shareholding percentage (35.00%) held by Financière de Tubize SA in UCB NV following the termination of a mutual agreement. This content directly relates to notifications about changes in significant share ownership thresholds, which corresponds to the Major Shareholding Notification category (MRQ). Although it is a regulatory disclosure, MRQ is more specific than the general RNS category.
2018-01-29 Dutch
UCB bimekizumab phase 2B results in PsA ENG
Earnings Release Classification · 95% confidence The document is a press release dated December 20, 2017, announcing positive top-line results from the Phase 2b BE ACTIVE study for the drug bimekizumab in treating psoriatic arthritis (PsA). It details efficacy endpoints (ACR50, PASI90) and compares results against placebo. The text explicitly states, 'UCB today announced that the Phase 2b BE ACTIVE study met the primary objective...' and includes sections like 'About Bimekizumab' and 'About Psoriatic Arthritis (PsA)'. This structure—announcing key results of a clinical trial—is characteristic of an Earnings Release (ER) or a general announcement related to clinical progress. Since it focuses on the *release* of clinical trial results and financial/operational updates are secondary (or absent, focusing purely on clinical data), it aligns best with an Earnings Release (ER) which often includes key operational/clinical milestones, or potentially an Investor Presentation (IP) if it were structured as slides, but as a press release announcing results, ER is the closest fit among the options for a major periodic update, even if not strictly quarterly earnings. Given the focus on clinical trial success and the announcement format, it is a form of results disclosure. It is not a full Annual Report (10-K), an Interim Report (IR), or a Call Transcript (CT). It is a formal announcement of results, making ER the most appropriate classification. Q4 2017
2017-12-20 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.